Freenome, Inc. · NASDAQ:FRNM
Freenome — Q3 2026 Earnings Presentation
23 slides from Freenome's earnings presentation, Nov 10, 2026
Slide 1: Q3 2026 Earnings Call and Business Update
Q3 2026 Earnings Call and Business Update November 10, 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the safe harbor provisions of the Private Securities Litigation
Slide 3: Freenome at a glance
Freenome at a glance Joined Nasdaq under “FRNM” & raised $310M in gross proceeds Our Mission Make early detection simple, accessible and affordable so cancer can be caught at its earliest, most treatable stages Founded 2014 AI-driven multiomics platform Personalized Cancer Detection approach Risk-ba
Slide 4: Cancer screening remains fragmented and underutilized
Cancer screening remains fragmented and underutilized Multiple, fragmented Only ~14% of cancers screening modalities are detected by exist today*1 screening 2 Colonoscopy / With a simple blood test … Stool Mammography / ~50% of cancers are MRI detected at advanced stage 3 Low-Dose CT Endoscopy / ~90
Slide 5: Freenome's Personalized Cancer Detection approach
Freenome’s Personalized Cancer Detection approach: One platform with single-cancer and multi-cancer tests Multi Cancer Single Cancer Planned Offering Detection (MCD) Detection (SCD) of SCD & MCD Tests ● 10+ indications ● Targets ~65% of diagnoses and ~70% of Multiple cancer deaths Cancers Multiple T
Slide 6: SimpleScreen CRC is FDA approved and commercially launched
SimpleScreen CRC is FDA approved and commercially launched ~60 million PREEMPT CRC: U.S. Census-adjusted analysis1 U.S. adults eligible for CRC screening who remain unscreened 81.1% 90.4% (nearly half the eligible population) CRC sensitivity Specificity Average-risk adults FDA approved in July 2026
Slide 7: Freenome's commercial strategy
Freenome’s commercial strategy Freenome’s commercial focus Commercial partner ecosystem Top-down health-system strategy Partner reach and capabilities ~625 73% U.S. standalone CRC U.S. health systems of providers affiliated Bottom-up primary care marketing with a health system ¹ SimpleScreen awarene
Slide 8: Partner reach and retained rights support two routes to market
Partner reach and retained rights support two routes to market Abbott standalone SimpleScreen CRC CRC Partner commercial reach Ordered alone Lab services (COGS) + 10% royalties 1,2 Freenome Tests and Freenome Personalized Cancer Detection lab infrastructure CRC ordered with any other single-cancer C
Slide 9: Abbott partnership and SimpleScreen CRC launch highlights
Abbott partnership and SimpleScreen CRC launch highlights Up to $885M Total potential payments Regulatory and market-access milestones and other conditions. Royalties in addition. U.S. launch: September 30, 2026 Received to date $242.2M ~800 ~380,000 >2,000 Sales reps Provider Clinical sites have In
Slide 10: Lung adds a second commercial test
Lung adds a second commercial test LDT clinical validation performance1 LDT 82% Stage I sensitivity launched Overall sensitivity 85% Adults age 50-80 Specificity 50% ≥20 pack-year smoking history Negative predictive value 99.8% Not up to date with annual low- dose CT screening Lung multiomics test ➔
Slide 11: Freenome's product and platform vision
Freenome’s product and platform vision Learning the Latent State of Multiple Diseases from Patients' Blood Over Time Cancer Signal of Origin Risk Stratification Early Disease Detection Care Navigation (CSO) Prediction Freenome Foundation Model cfDNA Sequence Proteomic Markers & Methylation Clinical
Slide 12: SimpleScreen CRC v2 met all primary and secondary endpoints
SimpleScreen CRC v2 met all primary and secondary endpoints Demonstrating improvements in advanced precancerous lesion (APL) and high-grade dysplasia (HGD) detection; CRC sensitivity in-line with v1 at 90% Specificity Assay and algorithm improvements within a year of the first version Modeled lifeti
Slide 13: A common platform to support different cancer tests
A common platform to support different cancer tests Discovery (R&D) Targeted Testing Individual Reports Multiomics Platform High-Throughput, Targeted Assays for Delivered Based on Broad Discovery Assays Commercial Applications Tests Ordered DNA Proteins RNA Other Assays selected for each test CRC An
Slide 14: Panel includes initial signatures for 10+ cancers
Panel includes initial signatures for 10+ cancers that cover ~65% of all cancer diagnoses and ~70% of cancer-related deaths Freenome’s partnership with Abbott and future commercial scale coupled with real-world data (RWD)* can potentially accelerate the development of the 10+ other cancer types in i
Slide 15: CRC screening provides a foundation for broader cancer detection
CRC screening provides a foundation for broader cancer detection and continuous learning through linked real-world data (RWD) Shared patient populations and health system relationships support portfolio expansion, while linked clinical outcomes inform future products. 84% of CRC-eligible patients el
Slide 16: Revenue of $183.5M driven by FDA approval of SimpleScreen CRC v1
Total revenue, 3Q26 Revenue of $183.5M driven by FDA approval of SimpleScreen CRC v1 $183.5M 3Q26 revenue by component ($M) vs. $1.0M in 3Q25 $180.0M Recognized under the Abbott collaboration after FDA approval of SimpleScreen CRC v1 (July 2026) • $157.5M exclusive commercialization license • $22.5M
Slide 17: Operating expenses increased on non-cash stock compensation
Operating expenses increased on non-cash stock compensation $113.5M Total operating expenses ($M) Total expenses Up $47.2M (+71.2%) vs. $66.3M in 3Q25 R&D G&A Cost of services 113.5 $68.4M R&D Up $17.8M (+35.1%) vs. 3Q25 44.6 Includes $9.9M of non-cash expense from restricted stock awards vesting at
Slide 18: Positive operating income, net income and Adjusted EBITDA
Positive operating income, net income and Adjusted EBITDA Operating income Net income ($0.58 diluted EPS1) Adjusted EBITDA2 $70.0M $60.1M $117.9M vs. $(65.3)M in 3Q25 vs. $(64.5)M, $(0.95) per share in 3Q25 vs. $(56.3)M in 3Q25 3Q25 3Q26 1. EPS based on 103.2M weighted-average diluted shares 2. Non-
Slide 19: 2026 Cash Runway and Revenue Guidance
2026 Cash Runway and Revenue Guidance Cash Balance $430M FY 2026 revenue guidance $192-194M Expected cash runway1 Into 2028 Full-year range reflects revenue recognized through 3Q26 plus Q4 guidance. 1. Based on current cash, cash equivalents and marketable securities. Excludes future milestone payme
Slide 20: Q&A
Freenome ::- Q&A
Slide 21: Appendix
Freenome ::- Appendix
Slide 22: Adjusted EBITDA Reconciliation
Adjusted EBITDA Reconciliation U.S. GAAP to non-GAAP, three months ended September 30, 2026 (unaudited) (in thousands) 3Q26 3Q26 bridge GAAP net income (loss) $60,110 Interest and investment income (2,969) $60.1M GAAP net income Interest expense 1,188 Other income (expense), net 6 +$57.8M Net adjust
Slide 23: Thank you
Freenome ::